Dafna Capital Management LLC Otonomy, Inc. Transaction History

Dafna Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.72 - $2.51 $46,981 - $68,560	-27,315 Reduced 1.82%	1,470,199 $3.06 Million
Q1 2022 May 16, 2022	SELL	$1.72 - $2.47 $1.21 Million - $1.74 Million	-702,783 Reduced 31.94%	1,497,514 $3.59 Million
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.31 $302,670 - $413,709	-179,095 Reduced 7.53%	2,200,297 $4.58 Million
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $4.1 Million - $5.31 Million	1,989,800 Added 510.74%	2,379,392 $5.31 Million
Q4 2020 Feb 16, 2021	SELL	$3.48 - $6.47 $1.04 Million - $1.94 Million	-299,508 Reduced 43.46%	389,592 $2.52 Million
Q3 2020 Nov 16, 2020	BUY	$3.16 - $4.36 $695,089 - $959,047	219,965 Added 46.89%	689,100 $2.79 Million
Q4 2019 Feb 14, 2020	BUY	$2.13 - $3.83 $999,257 - $1.8 Million	469,135 New	469,135 $1.8 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.